{"id":34005,"date":"2025-02-17T11:25:00","date_gmt":"2025-02-17T11:25:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4620584_AE20584_0"},"modified":"2025-02-17T11:25:00","modified_gmt":"2025-02-17T11:25:00","slug":"3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=34005","title":{"rendered":"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy"},"content":{"rendered":"<p><span class=\"legendSpanClass\"><span class=\"xn-location\">REYKJAVIK, Iceland<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Feb. 17, 2025<\/span><\/span> \/PRNewswire\/ &#8212; 3Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positions the mechanisms engaged by amlodipine, an L-type calcium channel&nbsp; blocker (LTCC), as a foundation for a novel therapy for ADHD. The findings provide robust validation of 3Z&#8217;s cutting-edge high-throughput drug discovery platform and introduce new avenues for non-stimulant-based ADHD treatment.<\/p>\n<p>ADHD is a prevalent neurodevelopmental disorder with limited treatment options. Current stimulant medications, such as methylphenidate, offer benefits to some but are often associated with side effects, abuse potential, and a high non-response rate. 3Z Pharmaceuticals is committed to addressing these gaps by pioneering alternative, non-stimulant therapeutics.<\/p>\n<p>In this newly published study, researchers at 3Z, integrated cross-species behavioral assays, Mendelian Randomization analysis, and human genetic data to demonstrate amlodipine&#8217;s therapeutic potential. Key findings include:<\/p>\n<ul type=\"disc\">\n<li>Behavioral Rescue in ADHD Models: Amlodipine significantly reduced hyperactivity in Spontaneously Hypertensive Rats and improved impulsivity in the adgrl3.1-\/- zebrafish model of ADHD, providing cross-species validation of its efficacy.<\/li>\n<li>Blood-Brain Barrier Penetration &amp; Neural Impact: Surprisingly traditional penetration studies confirmed that amlodipine crosses the blood-brain barrier, where it modulates neuronal activation, countering the assumption of poor brain penetration.<\/li>\n<li>Genetic Evidence via Mendelian Randomization: Human genetic analysis linked ADHD risk to variations in LTCC genes (CACNA1C, CACNB1, CACNA2D3), which are direct targets of amlodipine, reinforcing its mechanistic potential in ADHD therapy.<\/li>\n<li>Clinical Relevance in Human Populations: Polygenic risk score analysis using the UK Biobank demonstrated that individuals with a high ADHD genetic burden who were prescribed amlodipine exhibited reduced ADHD-related symptoms, independent of its antihypertensive effects.<\/li>\n<\/ul>\n<p>Dr. <span class=\"xn-person\">Karl Karlsson<\/span> a neuroscientist, CEO of 3Z Pharmaceuticals and Professor of Biomedical Engineering at <span class=\"xn-location\">Reykjavik<\/span> University, commented on the study&#8217;s impact:<\/p>\n<p><i>&#8220;This research represents a paradigm shift in ADHD therapeutics. Our findings not only validate the mechanism impacted by amlodipine as a promising candidate for non-stimulant ADHD treatment but also underscore the power of our high-throughput screening and genetic modeling approaches, performed in close alliance with biotx.ai. This is an exciting step forward in our mission to deliver more effective and well-tolerated treatments for ADHD.&#8221;<\/i><\/p>\n<p>Building on these findings, 3Z Pharmaceuticals is advancing a variant of the therapeutic towards clinical development, leveraging its established safety profile and precise mechanism of action to introduce transformative ADHD therapy.<\/p>\n<p><b>Media Contact:<br \/><\/b>Name: Karl \u00c6gir Karlson<br \/>Title: CEO<br \/>3Z Pharmaceuticals<br \/>Email: <a href=\"mailto:Karlsson@3z.is\" target=\"_blank\" rel=\"nofollow noopener\">Karlsson@3z.is<\/a><br \/>Phone: +354-8256467<\/p>\n<p>Link to paper:&nbsp;<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4363821-1&amp;h=1283987419&amp;u=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41386-025-02062-x&amp;a=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41386-025-02062-x\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/www.nature.com\/articles\/s41386-025-02062-x<\/a><\/p>\n<p>This information was brought to you by Cision <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4363821-1&amp;h=2688366151&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" target=\"_blank\" rel=\"nofollow noopener\">http:\/\/news.cision.com<\/a><\/p>\n<p><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4363821-1&amp;h=518239132&amp;u=https%3A%2F%2Fnews.cision.com%2F3z-ehf%2Fr%2F3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adh%2Cc4106638&amp;a=https%3A%2F%2Fnews.cision.com%2F3z-ehf%2Fr%2F3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adh%2Cc4106638\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/news.cision.com\/3z-ehf\/r\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adh,c4106638<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>REYKJAVIK, Iceland, Feb. 17, 2025 \/PRNewswire\/ &#8212; 3Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positions the mechanisms engaged by amlodipine, an L-type calcium channel&nbsp; blocker (LTCC), as a foundation for a novel therapy for ADHD. The findings provide robust validation of 3Z&#8217;s cutting-edge high-throughput drug [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-34005","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=34005\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy - My Blog\" \/>\n<meta property=\"og:description\" content=\"REYKJAVIK, Iceland, Feb. 17, 2025 \/PRNewswire\/ &#8212; 3Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positions the mechanisms engaged by amlodipine, an L-type calcium channel&nbsp; blocker (LTCC), as a foundation for a novel therapy for ADHD. The findings provide robust validation of 3Z&#8217;s cutting-edge high-throughput drug [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=34005\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-17T11:25:00+00:00\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=34005#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=34005\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy\",\"datePublished\":\"2025-02-17T11:25:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=34005\"},\"wordCount\":446,\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=34005\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=34005\",\"name\":\"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"datePublished\":\"2025-02-17T11:25:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=34005#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=34005\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=34005#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=34005","og_locale":"en_US","og_type":"article","og_title":"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy - My Blog","og_description":"REYKJAVIK, Iceland, Feb. 17, 2025 \/PRNewswire\/ &#8212; 3Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positions the mechanisms engaged by amlodipine, an L-type calcium channel&nbsp; blocker (LTCC), as a foundation for a novel therapy for ADHD. The findings provide robust validation of 3Z&#8217;s cutting-edge high-throughput drug [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=34005","og_site_name":"My Blog","article_published_time":"2025-02-17T11:25:00+00:00","author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=34005#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=34005"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy","datePublished":"2025-02-17T11:25:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=34005"},"wordCount":446,"articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=34005","url":"https:\/\/transmediavictoria.net.au\/?p=34005","name":"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"datePublished":"2025-02-17T11:25:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=34005#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=34005"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=34005#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/34005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34005"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/34005\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}